Miami-based TissueTech recently announced the completion of a $10 million round of growth equity financing from Ballast Point Ventures and River Cities Capital Funds.
TissueTech is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The funding will be largely used to accelerate commercial efforts and further research and development in both divisions, the company said.
Ballast Point Ventures, a later stage venture capital fund, is based in St. Petersburg. River Cities Capital Funds is headquartered in Cincinnati. Law firm Edwards Wildman represented the venture capital firms in the deal.